The U.S. Senate Judiciary Committee is set to discuss several proposed bills focusing on regulating patent-related practices in the pharmaceutical industry. Some bills involve examining the supply chain, while others are concerned with issues around drug patents. The Center for American Principles has raised alarms over the proposed legislation, arguing they're based on false data that experts at the U.S. Patent & Trademark Office have already debunked. CAP's Policy Fellow, Patrick Kilbride, emphasized the misleading nature of the data that influenced congressional decisions, calling for a rejection of the flawed legislation.
"Members of Congress were deliberately misled by years of falsified data that has been thoroughly debunked." - Patrick Kilbride, Policy Fellow, CAP
"Moved by allegations of 'evergreening' and 'product hopping' abuses, Members of Congress were deliberately misled by years of falsified data that has been thoroughly debunked by none other than the subject matter experts at the U.S. Patent & Trademark Office." - Patrick Kilbride, CAP
Collection
[
|
...
]